Clinical Trial Highlights

• No Survival Advantage to Using Bevacizumab as First-Line Therapy for Glioblastoma
• Predictive Molecular Biomarkers: Enriching Clinical Trial Populations for Glioblastoma
• Antiangiogenesis Therapy with Bevacizumab Improves Survival in Metastatic or Relapsed Cervical Cancer
• Sorafenib Delays Progression of Treatment-Resistant Differentiated Thyroid Cancer
• Tamoxifen in Estrogen Receptor-Positive Breast Cancer: 10 Years Superior to 5 Years
• Nintedanib Plus Docetaxel Improves PFS and OS for Patients with Stage IIIB/IV or Recurrent Lung Adenocarcinoma
• CENTRIC Trial Results
• Bevacizumab Monotherapy Improves DFI in Melanoma Patients at High Risk of Recurrence
• OPTiM Study Results
• FOLFIRI Plus Cetuximab Prolongs Overall mCRC Survival
• Final Results of AMAROS Trial
• Results from the LOGiC Trial
• Sequential Therapy Fails to Extend DFS in Gastric Cancer
• Chemoradiotherapy Fails to Improve Overall Survival in LAPC
• Targeting Telomerase with GV1001 Vaccine Does Not Prolong OS in Advanced Pancreatic Cancer
• Treatment Based on BRCA1 and RAP80 Does Not Extend PFS
• PRONOUNCE Study Results
• RIGHT Study Results
• Results from the EURAMOS-1 Trial